|
|
|
|
|
|
Sponsored by: |
Cedars-Sinai Medical Center |
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00064376 |
RATIONALE: Paricalcitol is a form of vitamin D that may help myelodysplastic cells develop into normal bone marrow cells.
PURPOSE: Phase II trial to study the effectiveness of paricalcitol in treating patients who have myelodysplastic syndrome.
Condition | Intervention | Phase |
Leukemia Myelodysplastic Syndromes |
Drug: paricalcitol |
Phase II |
MedlinePlus related topics: | Anemia Leukemia, Adult Acute Leukemia, Adult Chronic |
ChemIDplus related topics: | 19-Nor-1alpha,25-dihydroxyvitamin D2 |
Study Type: | Interventional |
Study Design: | Treatment, Open Label |
Official Title: | A Phase II Trial Of Paricalcitol In Myelodysplastic Syndromes |
Study Start Date: | May 2003 |
OBJECTIVES:
OUTLINE: Patients receive oral paricalcitol daily for 4 months in the absence of disease progression or unacceptable toxicity.
Patients are followed at 1 month.
PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study within 8 months.
Ages Eligible for Study: | 25 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Clinical diagnosis of myelodysplastic syndromes according to the modified FAB classification
PATIENT CHARACTERISTICS:
Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Other
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Other
United States, California | |||||
Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center | |||||
Los Angeles, California, United States, 90048 |
Cedars-Sinai Medical Center |
Study Chair: | H. Phillip Koeffler, MD | Cedars-Sinai Medical Center |
Clinical trial summary from the National Cancer Institute's PDQ® database 
  |
Study ID Numbers: | CDR0000315451, CSMC-IRB-4107-01 |
First Received: | July 8, 2003 |
Last Updated: | July 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00064376 |
Health Authority: | United States: Federal Government |
|
|
|
|
|